Mark Alan Goldberg
CIK 1532475 · EVP, Medical & Reg. Strategy · last filed 2025-07-21
Mark Alan Goldberg is an EVP, Medical & Reg. Strategy who has filed 124 SEC Form 4 insider transactions across 7 companies since 2011. The most recent filing, for BPMC, was dated Jul 21, 2025. Across all open-market trades the lifetime net is −$6.1M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
7
124
-$6.10M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) Delisted | Director | 0 | $129.46 | $0 | -$3.38M | 19 | 2025-07-21 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 36,325 | $15.70 | $570.3K | $49.6K | 15 | 2024-05-01 |
| ImmunoGen, Inc. (IMGN) Delisted | Director | 0 | $31.23 | $0 | $242.6K | 50 | 2024-02-12 |
| Aceragen, Inc. (IDRA) Delisted | Director | 48,610 | $7.22 | $351.2K | $31.9K | 16 | 2022-06-27 |
| BOLD | Director | 0 | $1.41 | $0 | $0 | 4 | 2020-01-15 |
| LIFE | Director | — | $15.61 | — | $0 | 4 | 2017-05-11 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | EVP, Medical & Reg. Strategy | 1,352 | — | — | -$3.04M | 16 | 2014-09-19 |
Recent Filings
124 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-21 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −22,156 | $0 | EDGAR |
| 2025-06-24 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +3,902 | $499.9K | EDGAR |
| 2024-06-14 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,242 | $0 | EDGAR |
| 2024-05-01 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-02 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +4,584 | $13.8K | EDGAR |
| 2024-02-12 | ImmunoGen, Inc. (IMGN) Delisted | Disp (D) | −60,720 | $0 | EDGAR |
| 2024-01-03 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | +569 | $16.9K | EDGAR |
| 2024-01-02 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +5,827 | $13.8K | EDGAR |
| 2023-11-01 | ImmunoGen, Inc. (IMGN) Delisted | Exer (M) | — | -$3.8K | EDGAR |
| 2023-10-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +9,167 | $13.8K | EDGAR |